Overview
Katherine Garbow is a Hematologist practicing medicine in Baltimore, Maryland. She has been practicing medicine for over 10 years.
Her clinical expertise encompasses Arterial Embolism.
She is actively involved in clinical research, co-authoring 1 peer reviewed article.
Graduate Year
Specialties
Licenses
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
201 E University Pkwy, Baltimore, MD 21218
9000 Franklin Square Dr, Baltimore, MD 21237
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.
Johns Hopkins Hospital
Michael Streiff is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Streiff is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration. Dr. Streiff is currently accepting new patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine. Dr. Dezern is currently accepting new patients.
Johns Hopkins University
Alison Moliterno is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Moliterno is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Moliterno is currently accepting new patients.
Johns Hopkins Hospital
Courtney Fitzhugh is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Fitzhugh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.
The Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, and Melanoma of the Eye. Dr. Lipson is board certified in American Board Of Internal Medicine. Dr. Lipson is currently accepting new patients.
Frequently Asked Questions about Dr. Katherine Garbow
How do I make an appointment with Dr. Katherine Garbow?
You can book an appointment with Dr. Katherine Garbow by calling their office at 410-554-2284. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Katherine Garbow a top-rated expert for Arterial Embolism?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Katherine Garbow is classified as an Experienced expert for Arterial Embolism, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Katherine Garbow specialize in?
While Dr. Katherine Garbow is a Hematology, they have specific expertise in Arterial Embolism. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.
Does Dr. Katherine Garbow participate in research or clinical trials?
Yes. Dr. Katherine Garbow has published 1 articles and abstracts on conditions like Arterial Embolism. You can view a list of Dr. Katherine Garbow's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Katherine Garbow accept my insurance?
Dr. Katherine Garbow accepts most major insurance plans, including Aetna and Blue Shield of California. We recommend calling the office directly at 410-554-2284 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers


